Carcinoembryonic Antigen (CEA) is a tumor marker in lung cancer.
CAT No: R1269
CAS No:168635-85-6
Synonyms/Alias:Carcinoembryonic Antigen CEA;168635-85-6;(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid;CARCINOEMBRYONIC ANTIGEN;Carcinoembryonic Antigen (CEA);AKOS040763953;DA-62064;MS-31810;G13358;(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-3-hydroxypropanamido]acetamido}propanamido]-3-carbamoylpropanamido]-4-methylpentanamido]-3-carbamoylpropanamido]-4-methylpentanoic acid;
Carcinoembryonic Antigen CEA is a well-characterized glycoprotein belonging to the immunoglobulin superfamily, commonly recognized as a tumor-associated marker with significant roles in cell adhesion processes. As a high-molecular-weight cell surface protein, it is expressed during fetal development and re-expressed in certain malignancies, particularly of the gastrointestinal tract. Its unique biochemical properties and expression profile have made it a focal point in cancer biology research, tumor marker development, and studies of cell-cell interactions. The molecular structure and immunogenicity of CEA provide a foundation for its broad utility in both fundamental and applied biochemical investigations.
Biomarker Research: CEA serves as a critical reference molecule in the development and validation of tumor biomarkers, especially for gastrointestinal and colorectal cancers. Researchers utilize purified CEA to evaluate antibody specificity, optimize immunoassays, and establish calibration standards for quantitative detection. Its well-documented overexpression in malignant tissues enables systematic studies of tumor progression, recurrence, and cellular differentiation, contributing to the refinement of diagnostic and prognostic tools.
Immunoassay Development: The antigen's stable epitopes and immunoreactivity make it an essential component in the design and optimization of enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, and other immunochemical platforms. By incorporating CEA as a positive control or analyte, assay developers can assess sensitivity, reproducibility, and antibody performance. Its use facilitates the creation of robust, reproducible testing systems for laboratory-based research applications.
Cell Adhesion and Signaling Studies: As a member of the immunoglobulin superfamily, CEA plays a functional role in mediating cell-cell adhesion and modulating intracellular signaling pathways. Biochemists and cell biologists employ CEA to dissect the molecular mechanisms underlying tissue architecture, metastatic dissemination, and cellular communication. Experimental models using this antigen provide valuable insights into the regulation of adhesion molecules and the dynamics of tumor cell invasion.
Antibody Production and Characterization: Purified CEA is widely used as an immunogen for generating monoclonal and polyclonal antibodies. These antibodies are indispensable for a range of downstream applications, including immunohistochemistry, flow cytometry, and western blotting. The antigen's defined structure and immunogenic domains support the production of high-affinity, target-specific antibodies, which are subsequently characterized for research and analytical purposes.
Molecular Interaction Analysis: The defined biochemical profile of CEA enables detailed studies of antigen-antibody interactions, epitope mapping, and ligand binding. By serving as a model system for affinity measurements and structural analyses, it helps elucidate the principles of molecular recognition and specificity. Researchers leverage these insights to inform the design of novel detection reagents, biosensors, and molecular probes for use in cancer research and diagnostic assay development.
1. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More